Course Outline

The Use of Cell Therapies for Autoimmune Diseases: MSCs from Biology to Clinical Application

SESSION 01 - Introduction: MSC for Treating Patients with Autoimmune Diseases: Dream of Reality?
LENGTH: 20 MINUTES

Speaker: Dominique Farge, MD, PhD, Professor of Internal Medicine, AP-HP St-Louis, Paris University, France

Learning Outcome:

  • An overview of the use of MSCs in autoimmune diseases

SESSION 02 - Mesenchymal Stem Cell (MSC) Biology
LENGTH: 26 MINUTES

Speaker: Karin Tarte, Pharm D, PhD, Director UMR U1236-MOBIDIC, Head of Honeycomb Research Team, Head of the Immunology Lab at Rennes University Hospital, Head of Rennes Immunomonitoring Platform (SITI), Medical School of Rennes, France

Learning Outcomes:

  • Differences between MSCs: Mesenchymal Stem Cells vs Mesenchymal Stromal Cells
  • Know  the MSCs  properties and their impact in clinical applications
  • Current defiition of MSC mechamism of action
  • What are the main issues considering the biological part of early MSC trials
  • Paramters to standaridze MSC evaluation

SESSION 03 - Umbilical Cord Blood Biology
LENGTH: 25 MINUTES

Speaker: Gesine Kogler, PhD, Professor, Heinrich Heine University Düsseldorf, Germany

Learning Outcomes:

  • Know the sources of MSCs
  • Phenotypic and functional characteristics (in-vivo and in-vitro) of MSCs derived from different sources
  • Understand the clincal potential of cord blood-derived stromal cells

SESSION 04 - Paracrine Mechanisms of Mesenchymal Stem Cells in Tissue Repair
LENGTH: 31 MINUTES

Speaker: Massimiliano Gnecchi, MD, PhD, FESC, Associate Professor of Cardiology, University of Pavia, Italy

Learning Outcome:

  • Case studies of the use of MSCs in tissue repair

SESSION 05 - Production, Regulation and Quality of MSC Cell Products
LENGTH: 25 MINUTES

Speaker: Fermin Sanchez-Guijo, MD, PhD, Head, Hematology Department, University Hospital of Salamanca, Spain

Learning Outcome:

  • Understand the activity & regulation of MSCs in Europe
  • Know the critical aspects for MSC production and management
  • Understand the role of of academic network (e.g. Spanish TerCel, TerAV) in MSC translation research

SESSION 06 - MSC: The First Success to Ongoing Developments (GVHD)
LENGTH: 23 MINUTES

Speaker: Katarina Le Blanc, MD, PhD, Professor, Karolinska Institute, Sweden

Learning Outcome:

  • Know the mechanisms of action behind GVHD
  • Case studies of the use of MSCs in GVHD

SESSION 07 - MSC for Crohn's Disease
LENGTH: 26 MINUTES

Speaker: Damian Garcia-Olmo, MD, PhD, Professor of Surgery, Autonomous University of Madrid, Spain

    Learning Outcome:

    • Case studies of the use of MSCs in Crohn's disease

    SESSION 08 - MSC for GI Diseases in Europe
    LENGTH: 20 MINUTES

    Speaker: Rachele Ciccocioppo, MD, Associate Professor of Gastroenterology, University of Verona, Italy

    Learning Outcome:

    • Know the objectives of therapy with mesenchymal stem/stromal cells in chronic gastrointestinal diseases
    • Case studies of the use of MSCs in GI disease

    SESSION 09 - Regulatory Framework For MSC Application in EMA
    LENGTH: 37 MINUTES

    Speaker: Lindsay Davies, BSc (Hons), PhD, FHEA, CEO and Founder CelLTherEx Consulting AB and CSO NextCell Pharma AB, Sweden

    Learning Outcome:

    • Know the definition of Advanced Therapeutic Medicinal Products (ATMPs)
    • Understand the ATMP governance and regulations under EMA
    • Understand the current challenges and next steps in MSC development for clinical applications
    SESSION 10 - MSC Umbilical Cord Blood Production For Clinical Trial?
    LENGTH: 39 MINUTES

    Speaker: Mark Lowdell, PhD, Professor, Cancer Institute, University College London, United Kingdom

    Learning Outcome:

    • Discuss some of the challenges with MSC product for clinical trials
    • Outline the process and requirements in manufacturing UCB-MSCs for clinical trials

    SESSION 11 - Statistical Considerations For Clinical Trial Design When Using MSC To Treat AD: How To Face With Heterogeneity
    LENGTH: 25 MINUTES

    Speaker: Lucie Biard, MD, PhD, Associate Professor in Biostatistics, University of Paris, France

    Learning Outcome:

    • Know some of the challenges in clinical research for auto-immune diseases
    • Understand the use of model-based designs, hierarchicial modeuls, and Bayseian trials for clinical trials

    SESSION 12 - MSC For RA Joints
    LENGTH: 25 MINUTES

    Speaker: Yves-Marie Pers, MD, PhD, Associate Professor in Biostatistics, University of Paris, France

    Learning Outcome:

    • Overview of Rheumatoid Arthritis (RA)  disease
    • Case studies of the use of MSCs for RA

    SESSION 13 - MSC For Systemic Sclerosis
    LENGTH: 22 MINUTES

    Speaker: Dominique Farge, MD, PhD, Professor of Internal Medicine, AP-HP St-Louis, Paris University, France

    Learning Outcome:

    • Case studies of the use of MSCs for Systemic Scierosis

    SESSION 14 - MSC For SLE
    LENGTH: 61 MINUTES

    Speaker: 

    • Lingyun Sun, MD, PhD, Professor, Department of Rheumatology and Immunology, Nanjing University Medical School, China
    • Gary Gilkeson, MD, Associate Dean and Professor, Medical University of South Carolina, USA

    Learning Outcome:

    • Case studies of the use of MSCs for Systemic lupus erythemotosus

    SESSION 15 - MSC For Neurological Diseases
    LENGTH: 39 MINUTES

    Speaker: Antonio Uccelli, MD, Professor of Neurology, University of Genoa, Italy

    Learning Outcome:

    • Case studies of the use of MSCs for Neurological diseases

    SESSION 16 - MSC For AUTISM
    LENGTH: 39 MINUTES

    Speaker: Joanne Kurtzberg, MD, Director, Marcus Center for Cellular Cures, Director, Carolinas Cord Blood Bank, Co-Director, Stem Cell Transplant Laboratory, Jerome Harris Distinguished Professor of Pediatrics, Professor of Pathology, Duke University, USA

    Learning Outcome:

    • Case studies of the use of MSCs for autism